Abstract
The current global debacle of COVID-19, spelled by SARS-CoV-2 needs no elaboration. With incessant and constantly clambering number of deaths across various nations, the need of the hour is to develop readily deployable, fast, affordable detection assays and kits, yielding precise and consistent results as well as timely availability of efficacious anti-SARS-CoV-2 strategies to contain it. Conventionally employed real time PCR based technique for detection of the virus suffers from a couple of handicaps. Amongst other approaches, CRISPR based technology has ushered in new hopes. Recent efforts have been directed toward developing CRISPR/Cas based low-cost, rapid detection methods as well as development of one-pot assay platforms. The plausible application of CRISPR-Cas system to counteract the viral assault has also been assessed. The write up in this article mirrors the current status, the prospects and the practical snags of CRISPR/Cas technology for the detection and inactivation of the novel corona virus, SARS-CoV-2.
Introduction
The constantly escalating number of articles in various scientific literature repositories attests the continual progress in the explication of the virology of SARS-CoV-2 and the pathogenesis of COVID-19 (; ; ; ; ; ; ). Various tactics for restricting the viral fusion/entry, interruption of the viral replication machinery, and suppression of inflammatory response, use of neutralizing antibodies including nanobodies and convalescent plasma treatment, besides the ongoing efforts and challenges in developing vaccines against SARS-CoV-2 are being appraised in a progressive context (; ; ). Howbeit, with the persistently increasing COVID-19 cases in various countries (), it becomes imperative to bring the detection-tests ‘closer’ to the patients and clinicians, particularly in terms of the cost, rapidity and ease of use. One may easily perceive the requisite to ramp up testing at a rapid pace in countries where the death toll is alarmingly high (). By the same token, media reports vouch for the criticism, faced by different countries for the pitiable mass testing proficiency, bracketed together with scarcity of COVID-19 testing kits (). On the other hand, asymptomatic transmission of the virus seems to be the Achilles’ heel amidst the current control strategies of the pandemic (; ). This further necessitates the extension and scale-up of SARS-CoV-2 assessment. Needless to stress that ascertaining foci of infections as well as reduction in false negative rates and elimination of ambiguity in results demand timely, pre-emptive and regular testing.
Pertinently, exploiting CRISPR/Cas (clustered regularly interspaced short palindromic repeats/CRISPR-associated) systems () for sensitive nucleotide detection has been an interesting endeavor in recent years (). Resorting to CRISPR/Cas systems for the diagnosis as well as inactivation of RNA and DNA viruses has opened up new portals in clinical virology (). These systems employ platforms like specific high sensitivity enzymatic reporter unlocking or SHERLOCK (), DNA endonuclease-targeted CRISPR trans reporter or DETECTR (), 1-h low-cost multipurpose highly efficient system or HOLMES () and Cas13-assisted restriction of viral expression and readout or CARVER (). To cite for evidence, SHERLOCK in combination with HUDSON (heating un-extracted diagnostic samples to obliterate nucleases) has been used directly to detect Zika and Dengue viruses from patients’ bodily fluids (). Such platforms are also being harnessed in the battle against SARS-CoV-2. These are expected to ease the burden placed on manufacturing potential for the costly conventional RT-qPCR testing reagents and consumables, dedicated instrumentation, and the absolute requisite of trained laboratory personnel that hinders widespread testing. However, it should be borne in mind that the various nucleic acid based detection-approaches like PCR, isothermal nucleic acid amplification-based methods, CRISPR/Cas platforms as well as immunoassay based point-of-care lateral flow tests are marked with their corresponding pros and cons (; ). Having said that, let us flick through some of the recent global endeavors in harnessing CRISPR/Cas technology to detect and target SARS-CoV-2 in the following section.
Prospects of CRISPR/Cas Systems for Detection and Inactivation of SARS-CoV-2
In the battle against the novel coronavirus, Sherlock Biosciences and Mammoth Biosciences have come up with innovative CRISPR platforms for COVID-19 diagnosis, facilitating visual readout. SHERLOCK platform targets two SARS-CoV-2 genes – the S gene and Orf1ab while Mammoth Biosciences’ platform DETECTR targets the N and E viral genes (). In a recent study, an inexpensive, fast (<40 min) and precise CRISPR-Cas12 based lateral flow assay- SARS-CoV-2 DETECTR for diagnosis of SARS-CoV-2 was reported (). The researchers had resorted to the use of contrived reference samples and clinical samples from infected US patients to attest the assay-performance in lines with the US CDC SARS-CoV-2 RT-PCR analysis. The protocol encompassed concomitant reverse transcription and isothermal amplification using loop-mediated amplification (RT-LAMP) from RNA, sampled from nasopharyngeal or oropharyngeal swabs in universal transport media (UTM). Cas12 assisted unmasking of predefined coronavirus sequences was followed by the cleavage of a reporter molecule, confirming the eventual detection of the virus. On a similar note, researchers from Argentina and CASPR Biotech, United States have described a CRISPR/Cas12 based ultrasensitive, fast and portable SARS-CoV-2 detection (). The suitability of using saliva specimens for diagnosis of COVID-19 was stressed upon in the report. Naturally occurring molecules in saliva did not seem to exert any inhibitory influence in the CRISPR based paper strip assay. With an objective to ensure an unambiguous detection of SARS-CoV-2, a cross-institutional work in China encompassed the designing of CRISPR RNAs (crRNAs) with the projected potency to discern single nucleotide polymorphisms (SNPs) from other SARS or SARS-related viruses, on the four domains of the orf1a, orf1b, N and E genes over the Wuhan-Hu-1 strain (GenBank accession number MN908947) (). Secondary structure and spacer sequence of the crRNA dictated the crRNA-dependent precise scissoring efficacy, eventually affecting the readout signal. Based on the sensitivity, indicated by fluorescence intensity, E-crRNAmix (against the target E gene) was employed in the screening of SARS-CoV-2 while orf1a-crRNAmix, orf1b-crRNAmix, N-crRNAmix were employed for additional confirmatory diagnosis. The authors validated their CRISPR/Cas12a-based- detection with naked eye readout (CRISPR/Cas12a-NER) assay (with an assay time of 15 min) in clinical diagnosis of COVID-19, demonstrating 100% agreement with qPCR assays, with the kappa value (κ) being 1.0 (P < 0.001).
On the other hand, a prospective CRISPR-novel Corona Virus (CRISPR-nCoV) test based on the concert of a recombinase polymerase amplification (RPA) step, subsequent T7 transcription and Cas13 detection step had been documented. With a near single-copy sensitivity and shorter turn-around time than RT-PCR, the approach demonstrated a cent percent clinical sensitivity in detecting 52 COVID-19 positive cases [confirmed by metagenomic next-generation sequencing (mNGS)], without any false positives for the 62 tested negative cases (). Similarly, had recently evaluated genomically-comprehensive machine learning SARS-CoV-2 assay designs based on CRISPR/Cas13 detection approach, incorporating synthetic targets with fluorescent and lateral flow detection. The detection of synthetic SARS-CoV-2 RNA was reported at 10 copies per microliter. However, assessing the sensitivity of the assay for clinical isolates and patient samples as well as demonstrating the specificity at species and subspecies levels of highly related viruses demand attention. In a similar vein, have recently proposed the application of CREST (Cas13-based, Rugged, Equitable, Scalable Testing) protocol as an orthogonal solution to augment testing potency for SARS-CoV-2. The approach involves the use of simple, easy to operate, portable thermocyclers and plastic-filter-based LED visualizers. The feasibility of documenting results with a smartphone camera and consequent uploading to the cloud is expected to facilitate point-of-care testing (POCT). At this juncture, it would be easily graspable that highly multiplexed CRISPR-based nucleic acid detection systems with feasibility to scale and miniaturize have the potency to shift diagnostic and surveillance endeavors from directed assessment of high-priority samples to all-inclusive testing of large sample groups. This would aid both patients and public health care practitioners. In this context, report evinced the fruition of a Combinatorial Arrayed Reactions for Multiplexed Evaluation of Nucleic acids Cas13 (CARMEN-Cas13) based multiplexed assay, capable of concomitant differentiation of 169 human-associated viruses with at least 10 published genome sequences (as on 24, October 2018). Besides efficient subtyping of influenza A strains and multiplexed discerning of HIV drug-resistance mutations, the platform was adapted promptly to slot in an additional crRNA for the detection of SARS-CoV-2. In fact, the authors have forwarded the possibility of single massive-capacity chip (mChip) -based parallel testing of 400 + samples against their coronavirus panel. By the same token, use of the mChip is expected to considerably cut down the reagent cost per test corresponding to standard multiwell-plate SHERLOCK tests, besides curtailing the number of protocol-steps and overall execution-time.
Although, these assays seem promising, the practical snags associated with the current CRISPR-based nucleic acid detection methods include the requisites of distinct nucleic acid amplification in various reaction platforms and numerous manual operations. The latter obfuscates the assessment protocols besides adding to the trouble of carry-over adulterations, attributed to the transfer of amplification products. In this context, from University of Connecticut Health Center have come up with an ‘All-In-One Dual CRISPR-Cas12a’ (termed ‘AIOD-CRISPR’) assay for low-cost, fast (typically 5–20 min), ultrasensitive, precise and visual detection of nucleic acid to assist clinicians. The various components for isothermal amplification and CRISPR-based detection can be prepared in a one-pot format, thereby, simplifying the detection procedures and abolishing the carry-over contamination-risks. The AIOD-CRISPR assay method could identify nucleic acids (DNA and RNA) of the SARS-CoV-2 and HIV-1 with a sensitivity of a few copies. Furthermore, a comparable sensitivity with RT-PCR was documented while detecting HIV-1 RNA of human plasma samples within less than 20 min. Integrating the AIOD-CRISPR assay into microfluidic diagnostic chip could result in realizing a simple, rapid and affordable point-of-care diagnostic platform for SARS-CoV-2 detection as well. By the same token, Guo et al. (2020) had coalesced sample treatment strategies and nucleic-acid amplification protocols to a previously reported Cas12b-mediated DNA detection (CDetection) (), leading to the establishment of a CASdetec (CRISPR assisted detection) platform, exhibiting a detection limit of 1 × 104 copies/mL for SARS-CoV-2 pseudovirus, without any cross-reactivity (Figure 1). The researchers employed a 7 nt poly-T fluorescence quencher and a single guide RNA-3, capable of discerning between the closely related SARS-CoV-2 and SARS-CoV, besides exhibiting the most distinct fluorescence signal. A hallmark feature of this study was the concurrent execution of the RT-recombinase aided amplification (RT-RAA) and CDetection within a single tube without lid-opening, thereby, lowering the risk of plausible aerosol contamination and associated false positives.
FIGURE 1
The afore-stated citations assuredly testify the immense prospects of harnessing CRISPR/Cas systems in the SARS-CoV-2 detection. As noted previously, companies like Mammoth Biosciences, Sherlock Biosciences and CASPR Biotech are currently devoting substantial time and resources to commercialize their respective CRISPR based diagnostic assays. Pertinently, under ‘emergency use’ provisions, the US Food and Drug Administration’s (FDA) emergency-use authority has recently approved a CRISPR-based diagnostic kit developed by Sherlock Biosciences to allay the COVID-19 detection backlogs in the US (). Similarly, in the Indian perspective, the Council of Scientific and Industrial Research’s (CSIR) component lab, Institute of Genomics and Integrative Biology (CSIR-IGIB) and TATA Sons have signed an MoU for licensing of ‘KNOWHOW’ for CRISPR based FNCAS9 Editor Linked Uniform Detection Assay (FELUDA) to cater to mass testing in a prompt manner ().
Deploying CRISPR/Cas system to combat viral assault seems to be another interesting proposition. Targeting the positive sense genome and viral mRNAs for concomitantly cleaving viral genome templates and shutting off their gene expression would be a stringent way to diminish the replication of SARS-CoV-2. In an earlier creditable attempt to harness Cas13’s tailorable RNA-targeting capacity, researchers from Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, United States reported an end-to-end technology platform, Cas13-assisted restriction of viral expression and readout (CARVER) (). The researchers assessed the efficacy of their programmed Cas13 in targeting three distinct ssRNA viruses- lymphocytic choriomeningitis virus (LCMV), influenza A virus (IAV), and vesicular stomatitis virus (VSV). The programmed Cas13 was robust enough to outshine the actively replicating and evolving viral RNA. Another facet of the study was the non-documentation of crRNA target site mutations (that might decrease the potency of antiviral strategies) following Cas13 treatment over 2-days period. Such multimodal tools are envisaged to permit both visualization and perturbation of viral replication with extremely high precision. A simple amendment of the crRNA sequence might assist in keeping pace with those viruses that plausibly tend to alter its own sequences as a consequence of therapy or in an outbreak. Elucidation of the precise action and efficacy of the tool for one virus is expected to enable the facile designing of sequences for various other viruses including SARS-CoV-2. Recently, considerable computational analysis and experimentations were put forth in a study streamlined in repurposing the RNA-guided RNA endonuclease activity of Cas13d in mammalian cells against SARS-CoV-2 and live influenza A virus (IAV) (). Screening a panel of crRNAs, targeting conserved viral regions, unveiled a group of six crRNAs that could target 91% of all coronaviruses and a group of 22 crRNAs with potential to target all sequenced coronaviruses with no mismatches. Limited by non-accessibility of widely available laboratory strains, the researchers resorted to synthesized fragments of SARS-CoV-2 (besides using live H1N1 IAV) to evaluate their Prophylactic Antiviral CRISPR in huMAN cells (PAC-MAN) strategy (). The PAC-MAN strategy was effective enough in degrading the SARS-CoV-2 sequences and live IAV genome in human lung epithelial cells (Figure 2). Pertinently, Cas13d could target conserved genomic regions of SARS-CoV-2, encoding the RNA-dependent RNA polymerase (RdRP) and nucleocapsid proteins that are of paramount importance for coronavirus replication and function.
FIGURE 2
Discussion and Conclusion
Post-perusal of the literature, cited in this article, one may easily perceive the prospects of employing CRISPR technology to address the viral assault as well as improve testing speed in the context of global paucity of timely COVID-19 tests. As far as the use of CRISPR technology for viral detection is concerned, researchers must address plausible off-target effects of CRISPR which might hinder the precise nucleotide detection (). The accuracy may also be affected as CRISPR/Cas effectors tend to show some sort of tolerance to mismatches between the guide RNA and target nucleotides. Furthermore, previous reports have evinced the failure of CRISPR to detect target DNA if the amplification product is < 1–10 nm within the reaction mix (). In this context, strategies to augment the molecular collisions between CRISPR and target (e.g., via enhancing the sgRNA concentrations, as exemplified in the work by ) could be instrumental in increasing reaction-rate as well as amplifying fluorescence-signal and the signal-to-background ratio.
study testifies the prospects of using CRISPR based systems to inactivate the virus. The researchers, however, did not conduct any animal studies. Ferrying the Cas13 in specific target-zones in a living person (in vivo delivery) could be a matter of concern. Although, the PAC-MAN approach () may be projected as a ‘potential pan-coronavirus line of attack’ the development of appropriate delivery platforms demands utmost deliberation. Nanobiomaterials may be assessed as prospective contrivance (). However, the combat zone in case of the coronavirus is the lung- comparatively inaccessible and mucus-packed that might interfere with the directed delivery. A combinatorial approach involving clinically administered drugs would be an interesting proposition to evaluate plausible synergistic viral inactivation. Assessment of the timescale and extent to which viral RNAs might evolve possible resistance to Cas13 targeting also demands attention. However, in the context of limited FDA-approved human trials of CRISPR technology for disease treatment, caution must be maintained vis-à-vis possible inflammation and other negative clinical repercussions. Validation of the promising approaches such as PAC-MAN and others using appropriate preclinical animal models or relevant organoid models and eventual clinical trials would obviously be a colossal and arduous task.
At this juncture, it is worthwhile to mention that CRISPR/Cas9 technology has also assisted researchers to generate human angiotensin converting enzyme 2 (hACE2, playing critical role in the viral pathogenesis) knock-in mice (). Remarkably, both young and aged hACE2 mice sustained elevated viral loads in lung, trachea, and brain post-intranasal infection in comparison to wild-type C57BL/6 mice while heightened cytokines level and interstitial pneumonia were documented in SARS-CoV-2 infected aged hACE2 mice. On the other hand, intragastric viral inoculation led to the establishment of infection and subsequent pulmonary pathological alterations in the hACE2 mice. Needless to say, appropriate animal models, recapitulating the clinical progression, evident in COVID-19 patients would support the investigations pertaining to SARS-CoV-2 infection and transmission, besides assisting research-activities to find prospective vaccines and therapeutics.
It is also to be noted that ACE2 receptors are present in key metabolic organs and tissues, including kidneys and the pancreatic β-cells. Besides various autoinflammatory/autoimmune conditions (), a couple of recent observations have also evinced potential diabetogenic effect of COVID-19 (; Ren et al., 2020; ). Attributable to the tropism of SARS-CoV-2 for the pancreatic β-cells and impairment of their function in concert with the cytokine storm and counter-regulatory hormonal responses, new-onset diabetes besides severe metabolic complications of preexisting diabetes, including diabetic ketoacidosis and hyperosmolarity could set in patients with COVID-19 (; Ren et al., 2020; ). On the other hand, worse consequences are observed in COVID-19 patients presented with diabetes, bracketed together with a range of associated conditions augmenting the risk (). Hyper and hypoglycemia could both be projected as plausible predictors of mortality in critically ill individuals in COVID-19 (; ). In the context of the afore-stated biunivocal link between COVID-19 and diabetes, CRISPR-Cas tools hold the potential to offer exceptional experimental strategies to elucidate the mechanisms of β-cell functions, besides the plausibility of generating gene knockouts and diabetic mouse models, amending and introducing point mutations, engineering fluorescent reporter cell lines and modulating transcription (; ; ). As a piece of exemplary evidence, had reported the development of a robust pipeline to generate a stable CRISPR/Cas9 gene knockout in the human β-cell line, EndoC-βH1, to have a better insight into the genes engaged in β-cell malfunction and T2DM pathogenesis. In another report, a CRISPR/Cas9 conjugation platform was harnessed to engineer INS-1E β-cells with an objective to repurpose the insulin-releasing biomachinery, leading to glucose-dependent release of IL-10, an immunomodulatory factor (). CRISPR/Cas9-engineered β-cells have also been explored to characterize the pharmacology of compounds with activity at both glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R) (). Similarly, injection of lecithin based nanoliposomal carrier of CRISPR/Cas9 directly into type 2 diabetes mellitus (T2DM) db/db mice was reported to disrupt expression of dipeptidyl peptidase-4 (DPP-4) gene, consequently lowering the DPP-4 enzyme activity, complemented by normalized blood glucose levels, insulin response, and lessened organ destruction (). In another pertinent work, had resorted to CRISPR/Cas system to rectify a Wolfram syndrome 1 (WFS1) (characterized by a gamut of symptoms including diabetes, optic atrophy, etc.) pathogenic variant in patient fibrobrast-derived induced pluripotent stem cells (iPSCs), followed by six-stage differentiation to pancreatic β-cells. The amended SC- β-cells exhibited up-scaled insulin secretion, dip in the expression of genes linked to endoplasmic reticulum stress as well as the reversal of hyperglycemia for half-a-year post-transplantation into diabetic mice. These studies obviously raise hopes and anticipations in harnessing CRISPR/Cas tools to address diabetic status, particularly in the milieu of the growing evidence of the link between diabetes and COVID-19. Nevertheless, the readers are suggested to peruse the recent retrospect article by on the prospects and challenges of genome editing of human pancreatic β-cell models.
On a concluding note, a recent article by , published in The Conversation merits special mention. Post-emulating the plausibility of using CRISPR to (a) edit and inactivate the SARS-CoV-2 genome and (b) develop COVID-19 diagnostic platforms, the write-up is winded up with a question, germane to the context: ‘In case, we fail to contain the virus, would/should we resort to CRISPR/Cas based gene editing in humans to possibly nullify the chances of getting infected?’ In this regard, the ethical and legal considerations pertaining to CRISPR based genome editing research must be acknowledged and prudently deliberated in the process of determining the application of the technology (). Particularly, in the case of at-home application, researchers are apprehensive about the plausible ethical challenges with respect to data sharing/patient privacy and issues pertaining to the requirement for befitting clinical counseling post-obtaining of the test results (). Nevertheless, the development of facile, robust, high accuracy, sensitive, affordable and point-of-care diagnostics for early detection of SARS-CoV-2 virus at home or in small clinics is the need of the hour to expedite intervention and treatment as well as to thwart the spread of COVID-19. It is highly anticipated that biotechnological advancements and concerted efforts of various researchers would surely open the avenue to a world free from the clutches of COVID-19 (and alike).
Statements
Author contributions
RK reviewed the literature, critically analyzed it, and drafted the manuscript.
Acknowledgments
A bouquet of gratitude is extended to all those researchers, who are engaged in devising befitting strategies against COVID-19. The doctors, nurses, and other frontline warriors during this tough time are thankfully acknowledged.
Conflict of interest
The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
AbbottT. R.DhamdhereG.LiuY.LinX.GoudyL. E.ZengL.et al (2020). Development of CRISPR as a prophylactic strategy to combat novel coronavirus and influenza.Cell181865–876.e12. 10.1016/j.cell.2020.04.020
2
AckermanC. M.MyhrvoldC.ThakkuS. G.FreijeC. A.MetskyH. C.YangD. K.et al (2020). Massively multiplexed nucleic acid detection with Cas13.Nature582277–282. 10.1038/s41586-020-2279-8
3
Al Jazeera and News Agencies (2020). India’s Poor Testing Rate May Have Masked Coronavirus Cases. Available online at: https://www.aljazeera.com/news/2020/03/india-poor-testing-rate-masked-coronavirus-cases-200318040314568.html(Accessed June 23, 2020)
4
AloysiusM. M.ThattiA.GuptaA.SharmaN.BansalP.GoyalH. (2020). COVID-19 presenting as acute pancreatitis. Pancreatology20, 1026–1027. 10.1016/j.pan.2020.05.003
5
ApicellaM.CampopianoM. C.MantuanoM.MazoniL.CoppelliA.Del PratoS. (2020). COVID-19 in people with diabetes: understanding the reasons for worse outcomes.Lancet Diabetes Endocrinol.8782–792. 10.1016/S2213-8587(20)30238-2
6
BaiH.CaiX.ZhanX. (2020). Landscape Coronavirus Disease 2019 test (COVID-19 test) in vitro- A comparison of PCR vs Immunoassay vs CRISPR-Based Test.Peoria, III: OSF10.31219/osf.io/6eagn
7
BalboaD.PrasadR. B.GroopL.OtonkoskiT. (2019). Genome editing of human pancreatic beta cell models: problems, possibilities and outlook.Diabetologia621329–1336. 10.1007/s00125-019-4908-z
8
BoltL. M. (2019). The Promise of CRISPR-based Diagnostics.Clin. Lab Manag. Available online at: https://www.clinicallabmanager.com/q-and-a/the-promise-of-crispr-based-diagnostics-274#:~:text=A%3A%20CRISPR%20is%20an%20ancient,can%20cut%20DNA%20or%20RNA.&text=While%20CRISPR%2Dbased%20diagnostics%20are,CRISPR%20has%20huge%20medical%20potential(accessed August 18, 2020).
9
BroughtonJ. P.DengX.YuG.FaschingC. L.ServellitaV.SinghJ.et al (2020). CRISPR–Cas12-based detection of SARS-CoV-2. Nat. Biotechnol.38, 870–874. 10.1038/s41587-020-0513-4
10
ChanW. C. (2020). Nano research for COVID-19.ACS Nano143719–3720. 10.1021/acsnano.0c02540
11
ChenJ. S.MaE.HarringtonL. B.Da CostaM.TianX.PalefskyJ. M.et al (2018). CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity.Science360436–439. 10.1126/science.aar6245
12
ChenW.FengP.LiuK.WuM.LinH. (2020). Computational identification of small interfering RNA targets in SARS-CoV-2.Virol. Sin.35359–361. 10.1007/s12250-020-00221-6
13
ChoE. Y.RyuJ. Y.LeeH. A. R.HongS. H.ParkH. S.HongK. S.et al (2019). Lecithin nano-liposomal particle as a CRISPR/Cas9 complex delivery system for treating type 2 diabetes.J. Nanobiotechnol.17:19. 10.1186/s12951-019-0452-8
14
CodoA. C.DavanzoG. G.MonteiroL. B.SouzaG.MuraroS.CarregariV.et al (2020). Elevated glucose levels favor SARS-CoV-2 infection and monocyte response through a HIF-1α/glycolysis dependent axis. Cell Metab.437–446.e5. 10.1016/j.cmet.2020.07.007
15
DayM. (2020). COVID-19: four fifths of cases are asymptomatic.China Fig. Indicate.369:m1375. 10.1136/bmj.m1375
16
DingX.YinK.LiZ.LiuC. (2020). All-in-One dual CRISPR-Cas12a (AIOD-CRISPR) Assay: a case for rapid, ultrasensitive and visual detection of novel coronavirus SARS-CoV-2 and HIV virus.bioRxiv10.1101/2020.03.19.998724 [Preprint]
17
FreijeC. A.MyhrvoldC.BoehmC. K.LinA. E.WelchN. L.CarterA.et al (2019). Programmable inhibition and detection of RNA viruses using Cas13.Mol. Cell76826–837.e11. 10.1016/j.molcel.2019.09.013
18
GandhiM.YokoeD. S.HavlirD. V. (2020). Asymptomatic transmission, the Achilles’ heel of current strategies to control COVID-19.N. Engl. J. Med.3822158–2160. 10.1056/NEJMe2009758
19
GootenbergJ. S.AbudayyehO. O.LeeJ. W.EssletzbichlerP.DyA. J.JoungJ.et al (2017). Nucleic acid detection with CRISPR-Cas13a/C2c2.Science356438–442. 10.1126/science.aam9321
20
GrotzA. K.AbaituaF.Navarro-GuerreroE.HastoyB.EbnerD.GloynA. L. (2019). A CRISPR/Cas9 genome editing pipeline in the EndoC-βH1 cell line to study genes implicated in beta cell function.Wellcome Open Res.4:150. 10.12688/wellcomeopenres.15447.2
21
GuoL.SunX.WangX.LiangC.JiangH.GaoQ.et al (2020). SARS-CoV-2 detection with CRISPR diagnostics.Cell Discov.6:34. 10.1038/s41421-020-0174-y
22
HouT.ZengW.YangM.ChenW.RenL.AiJ.et al (2020). Development and Eevaluation of a CRISPR-based diagnostic for 2019-novel coronavirus.Med Rxiv10.1101/2020.02.22.20025460 [Preprint].
23
JiaF.LiX.ZhangC.TangX. (2020). The expanded development and application of CRISPR system for sensitive nucleotide detection.Protein Cell20201–6. 10.1007/s13238-020-00708-8
24
JiangS.HillyerC.DuL. (2020). Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses.Trends Immunol.41355–359. 10.1016/j.it.2020.03.007
25
KhanS. H. (2019). Type-2 diabetes and gene therapy-The promise of CRISPR gene therapy in type-2 diabetes mellitus.Glob. J. Obes. Diabetes Metab. Syndr.6022–024. 10.17352/2455-8583.000038
26
KonwarhR. (2020). Nanobodies: prospects of expanding the gamut of neutralizing antibodies against the novel coronavirus, SARS-CoV-2.Front. Immunol.11:1531. 10.3389/fimmu.2020.01531
27
LiL.LiS.WuN.WuJ.WangG.ZhaoG.et al (2019). HOLMESv2: a CRISPR-Cas12b-assisted platform for nucleic acid detection and DNA methylation quantitation.ACS Synth. Biol.82228–2237. 10.1021/acssynbio.9b00209
28
LiH.ZhouY.ZhangM.WangH.ZhaoQ.LiuJ. (2020a). Updated approaches against SARS –CoV-2.Antimicrob. Agents Chemother.64:e00483-20. 10.1128/AAC.00483-20
29
LiX.GengM.PengY.MengL.LuS. (2020b). Molecular immune pathogenesis and diagnosis of COVID-19.J. Pharm. Anal.10102–108. 10.1016/j.jpha.2020.03.001
30
LimD.SreekanthV.CoxK. J.LawB. K.WagnerB. K.KarpJ. M.et al (2020). Engineering designer beta cells with a CRISPR-Cas9 conjugation platform.Nat. Commun.11:4043. 10.1038/s41467-020-17725-0
31
LuciaC.FedericoP. B.AlejandraG. C. (2020). An ultrasensitive, rapid, and portable coronavirus SARS-CoV-2 sequence detection method based on CRISPR-Cas12.bioRxiv10.1101/2020.02.29.971127 [Preprint].
32
MakarovaK. S.WolfY. I.IranzoJ.ShmakovS. A.AlkhnbashiO. S.BrounsS. J.et al (2020). Evolutionary classification of CRISPR–Cas systems: a burst of class 2 and derived variants.Nat. Rev. Microbiol.1867–83. 10.1038/s41579-019-0299-x
33
MaxwellK. G.AugsornworawatP.Velazco-CruzL.KimM. H.AsadaR.HogrebeN. J.et al (2020). Gene-edited human stem cell–derived β cells from a patient with monogenic diabetes reverse preexisting diabetes in mice.Sci. Transl. Med.12:eaax9106. 10.1126/scitranslmed.aax9106
34
Médecins Sans Frontières (2020). Brazil’s COVID-19 Nightmare is Far from Under Control. Available online at: https://www.msf.org/coronavirus-covid-19-nightmare-continues-brazil(Accessed June 23, 2020)
35
MetskyH. C.FreijeC. A.Kosoko-ThoroddsenT. S. F.SabetiP. C.MyhrvoldC. (2020). CRISPR-based surveillance for COVID-19 using genomically-comprehensive machine learning design.bioRxiv10.1101/2020.02.26.967026 [Preprint].
36
MonteilV.KwonH.PradoP.HagelkrüysA.WimmerR. A.StahlM.et al (2020). Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2.Cell181905–913.e7. 10.1016/j.cell.2020.04.004
37
MyhrvoldC.FreijeC. A.GootenbergJ. S.AbudayyehO. O.MetskyH. C.DurbinA. F.et al (2018). Field-deployable viral diagnostics using CRISPR-Cas13.Science360444–448. 10.1126/science.aas8836
38
NaylorJ.SuckowA. T.SethA.BakerD. J.SermadirasI.RavnP.et al (2016). Use of CRISPR/Cas9-engineered INS-1 pancreatic β cells to define the pharmacology of dual GIPR/GLP-1R agonists.Biochem. J.4732881–2891. 10.1042/bcj20160476
39
NiemiecE.HowardH. C. (2020). Ethical issues related to research on genome editing in human embryos.Comput. Struct. Biotechnol. J.18887–896. 10.1016/j.csbj.2020.03.014
40
PiarulliF.LapollaA. (2020). COVID 19 and low-glucose levels: is there a link?Diabetes Res. Clin. Pract.108283 (in press). 10.1016/j.diabres.2020.108283
41
PrabhuneM. (2020). Coronavirus Detection Using CRISPR Diagnostics. Synthego. Available online at: https://www.synthego.com/blog/crispr-coronavirus-detection. (Accessed April 5, 2020)
42
RabiF. A.Al ZoubiM. S.KasasbehG. A.SalamehD. M.Al-NasserA. D. (2020). SARS-CoV-2 and coronavirus disease 2019: what we know so far.Pathogens9:231. 10.3390/pathogens9030231
43
RauchJ. N.ValoisE.SolleyS. C.BraigF.LachR. S.BaxterN. J.et al (2020). A scalable, easy-to-deploy, protocol for Cas13-based detection of SARS-CoV-2 genetic material.bioRxiv10.1101/2020.04.20.052159 [Preprint].
44
RenH.YangY.WangF.YanY.ShiX.DongK.et al (2020). Association of the insulin resistance marker TyG index with the severity and mortality of COVID-19. Cardiovasc. Diabetol.19:58. 10.1186/s12933-020-01035-2
45
RodríguezY.NovelliL.RojasM.De SantisM.Acosta-AmpudiaY.MonsalveD. M.et al (2020). Autoinflammatory and autoimmune conditions at the crossroad of COVID-19. J. Autoimmun.102506 (in press). 10.1016/j.jaut.2020.102506
46
RohJ. I.LeeJ.ParkS. U.KangY. S.LeeJ.OhA. R.et al (2018). CRISPR-Cas9-mediated generation of obese and diabetic mouse models.Exp. Anim.67229–237. 10.1538/expanim.17-0123
47
RubinoF.AmielS. A.ZimmetP.AlbertiG.BornsteinS.EckelR. H.et al (2020). New-Onset Diabetes in COVID-19.N. Engl. J. Med.2020:NEJMc2018688. 10.1056/NEJMc2018688
48
SarkarS. (2020). CSIR-IGIB and TATA Sons sign MoU for licensing ‘KNOWHOW’ for rapid diagnosis of Covid-19. Hindustan Times. Available online at: https://www.hindustantimes.com/business-news/csir-igib-and-tata-sons-sign-mou-for-licensing-knowhow-for-rapid-diagnosis-of-covid-19/story-QKf9Y5c2atsabpMEyr2jIN.html, (accessed June 23, 2020)
49
SatyanarayanaM. (2020). A COVID-19 diagnostic that uses CRISPR gets a nod from the FDA Chemical & Engineering News. Available online at: https://cen.acs.org/analytical-chemistry/diagnostics/COVID-19-diagnostic-uses-CRISPR/98/web/2020/05(accessed June 23, 2020).
50
ShenM.ZhouY.YeJ.Al-maskriA. A. A.KangY.ZengS.et al (2020). Recent advances and perspectives of nucleic acid detection for coronavirus.J. Pharm. Anal.1097–101. 10.1016/j.jpha.2020.02.010
51
SoniS. (2020). COVID-19 and gene editing: ethical and legal considerations.Conversation. Available online at: https://theconversation.com/covid-19-and-gene-editing-ethical-and-legal-considerations-138164(accessed June 24, 2020).
52
SunS. H.ChenQ.GuH. J.YangG.WangY. X.HuangX. Y.et al (2020). A mouse model of SARS-CoV-2 infection and pathogenesis.Cell Host Microbe28124–133.e4. 10.1016/j.chom.2020.05.020
53
TengF.GuoL.CuiT.WangX. G.XuK.GaoQ.et al (2019). CDetection: CRISPR-Cas12b-based DNA detection with sub-attomolar sensitivity and single-base specificity.Genome Biol.20:132. 10.1186/s13059-019-1742-z
54
WanY.ShangJ.GrahamR.BaricR. S.LiF. (2020). Receptor recognition by novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS.J. Virol.94:e00127-120. 10.1128/JVI.00127-120
55
WangX.ZhongM.LiuY.MaP.DangL.MengQ.et al (2020). Rapid and sensitive detection of COVID-19 using CRISPR/Cas12a-based detection with naked eye readout, CRISPR/Cas12a-NER.Sci. Bull. (Beijing)651436–1439. 10.1016/j.scib.2020.04.041
56
World Health Organization (2020). WHO Coronavirus Disease (COVID-19) Dashboard.Geneva: World Health Organization.
57
WuY. (2020). Compensation of ACE2 Function for possible clinical management of 2019-nCoV-induced acute lung injury.Virol. Sin35256–258. 10.1007/s12250-020-00205-6
58
XieM.ChenQ. (2020). Insight into 2019 novel coronavirus—an updated interim review and lessons from SARS-CoV and MERS-CoV.Int. J. Infect. Dis.94119–124. 10.1016/j.ijid.2020.03.071
Summary
Keywords
COVID-19, SARS-CoV-2, CRISPR/Cas, diagnostics, viral inactivation, RNA
Citation
Konwarh R (2020) Can CRISPR/Cas Technology Be a Felicitous Stratagem Against the COVID-19 Fiasco? Prospects and Hitches. Front. Mol. Biosci. 7:557377. doi: 10.3389/fmolb.2020.557377
Received
30 April 2020
Accepted
19 August 2020
Published
10 September 2020
Volume
7 - 2020
Edited by
Chi Shing Cho, QEH, Hong Kong
Reviewed by
Azamal Husen, Wolaita Sodo University, Ethiopia; Sayed Haidar Abbas Raza, Northwest A&F University, China
Updates
Copyright
© 2020 Konwarh.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Rocktotpal Konwarh, rocktotpal.konwarh@aastu.edu.et; rock1311@gmail.com
This article was submitted to Molecular Diagnostics and Therapeutics, a section of the journal Frontiers in Molecular Biosciences
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.